327 related articles for article (PubMed ID: 16612252)
1. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.
Mahapatra NR; Mahata M; Mahata SK; O'Connor DT
J Hypertens; 2006 May; 24(5):895-904. PubMed ID: 16612252
[TBL] [Abstract][Full Text] [Related]
2. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses.
Mahata SK; Mahata M; Wen G; Wong WB; Mahapatra NR; Hamilton BA; O'Connor DT
Mol Pharmacol; 2004 Nov; 66(5):1180-91. PubMed ID: 15326220
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism.
Taupenot L; Mahata SK; Mahata M; Parmer RJ; O'Connor DT
Regul Pept; 2000 Nov; 95(1-3):9-17. PubMed ID: 11062327
[TBL] [Abstract][Full Text] [Related]
4. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.
Mahata SK; O'Connor DT; Mahata M; Yoo SH; Taupenot L; Wu H; Gill BM; Parmer RJ
J Clin Invest; 1997 Sep; 100(6):1623-33. PubMed ID: 9294131
[TBL] [Abstract][Full Text] [Related]
5. Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis.
Herrero CJ; Alés E; Pintado AJ; López MG; García-Palomero E; Mahata SK; O'Connor DT; García AG; Montiel C
J Neurosci; 2002 Jan; 22(2):377-88. PubMed ID: 11784782
[TBL] [Abstract][Full Text] [Related]
6. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance.
Mahata SK; Mahata M; Parmer RJ; O'Connor DT
J Biol Chem; 1999 Jan; 274(5):2920-8. PubMed ID: 9915830
[TBL] [Abstract][Full Text] [Related]
7. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.
Mahata SK; Mahapatra NR; Mahata M; Wang TC; Kennedy BP; Ziegler MG; O'Connor DT
J Biol Chem; 2003 Aug; 278(34):32058-67. PubMed ID: 12799369
[TBL] [Abstract][Full Text] [Related]
8. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.
Mahata SK; Mahata M; Wakade AR; O'Connor DT
Mol Endocrinol; 2000 Oct; 14(10):1525-35. PubMed ID: 11043569
[TBL] [Abstract][Full Text] [Related]
9. A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis.
Mahata SK; Mahata M; Yoo SH; Taupenot L; Wu H; Aroda VR; Livsey CV; Taulane JP; Goodman M; Parmer RJ; O'Connor DT
Adv Pharmacol; 1998; 42():260-4. PubMed ID: 9327894
[No Abstract] [Full Text] [Related]
10. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
Taylor CV; Taupenot L; Mahata SK; Mahata M; Wu H; Yasothornsrikul S; Toneff T; Caporale C; Jiang Q; Parmer RJ; Hook VY; O'Connor DT
J Biol Chem; 2000 Jul; 275(30):22905-15. PubMed ID: 10781584
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity.
Tsigelny I; Mahata SK; Taupenot L; Preece NE; Mahata M; Khan I; Parmer RJ; O'Connor DT
Regul Pept; 1998 Oct; 77(1-3):43-53. PubMed ID: 9809795
[TBL] [Abstract][Full Text] [Related]
12. Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic (PACAPergic) stimulation in PC12 cells.
Sahu BS; Mahata S; Bandyopadhyay K; Mahata M; Avolio E; Pasqua T; Sahu C; Bandyopadhyay GK; Bartolomucci A; Webster NJG; Van Den Bogaart G; Fischer-Colbrie R; Corti A; Eiden LE; Mahata SK
Cell Tissue Res; 2019 Apr; 376(1):51-70. PubMed ID: 30467710
[TBL] [Abstract][Full Text] [Related]
13. Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.
Toneff T; Funkelstein L; Mosier C; Abagyan A; Ziegler M; Hook V
Peptides; 2013 Aug; 46():126-35. PubMed ID: 23747840
[TBL] [Abstract][Full Text] [Related]
14. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.
Lee JC; Taylor CV; Gaucher SP; Toneff T; Taupenot L; Yasothornsrikul S; Mahata SK; Sei C; Parmer RJ; Neveu JM; Lane WS; Gibson BW; O'Connor DT; Hook VY
Biochemistry; 2003 Jun; 42(23):6938-46. PubMed ID: 12795588
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides.
Biswas N; Rodriguez-Flores JL; Courel M; Gayen JR; Vaingankar SM; Mahata M; Torpey JW; Taupenot L; O'Connor DT; Mahata SK
Endocrinology; 2009 Aug; 150(8):3547-57. PubMed ID: 19372204
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A: a surprising link between granule biogenesis and hypertension.
Kim T; Loh YP
J Clin Invest; 2005 Jul; 115(7):1711-3. PubMed ID: 16007250
[TBL] [Abstract][Full Text] [Related]
17. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release.
Takiyyuddin MA; Brown MR; Dinh TQ; Cervenka JH; Braun SD; Parmer RJ; Kennedy B; O'Connor DT
J Auton Pharmacol; 1994 Jun; 14(3):187-200. PubMed ID: 7929473
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic concentrations of varenicline increases exocytotic release of catecholamines from human and rat adrenal chromaffin cells in the presence of nicotine.
Jiménez-Pompa A; Sanz-Lázaro S; Hone AJ; Rueda-Ruzafa L; Medina-Polo J; González-Enguita C; Blázquez J; de Los Ríos C; Michael McIntosh J; Albillos A
Neuropharmacology; 2021 Sep; 195():108632. PubMed ID: 34097947
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion.
Greenwood TA; Rao F; Stridsberg M; Mahapatra NR; Mahata M; Lillie EO; Mahata SK; Taupenot L; Schork NJ; O'Connor DT
Physiol Genomics; 2006 May; 25(3):470-9. PubMed ID: 16554546
[TBL] [Abstract][Full Text] [Related]
20. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.
Mahapatra NR; O'Connor DT; Vaingankar SM; Hikim AP; Mahata M; Ray S; Staite E; Wu H; Gu Y; Dalton N; Kennedy BP; Ziegler MG; Ross J; Mahata SK
J Clin Invest; 2005 Jul; 115(7):1942-52. PubMed ID: 16007257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
